Acute myeloid leukemia

KIT pathway upregulation predicts dasatinib efficacy in acute myeloid leukemia

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Fig. 1: Dasatinib has high sensitivity in AML patient samples compared to AML cell lines.
Fig. 2: KIT pathway enrichment is associated with dasatinib efficacy.


  1. 1.

    Döhner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Büchner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129:424–47.

    Article  Google Scholar 

  2. 2.

    Pemovska T, Kontro M, Yadav B, Edgren H, Eldfors S, Szwajda A, et al. Individualized Systems Medicine Strategy to Tailor Treatments for Patients with Chemorefractory Acute Myeloid Leukemia. Cancer Discov. 2013;3:1416–29.

    CAS  Article  Google Scholar 

  3. 3.

    Tyner JW, Tognon CE, Bottomly D, Wilmot B, Kurtz SE, Savage SL, et al. Functional genomic landscape of acute myeloid leukaemia. Nature. 2018; 562:526–31.

  4. 4.

    Snijder B, Vladimer GI, Krall N, Miura K, Schmolke A-S, Kornauth C, et al. Image-based ex-vivo drug screening for patients with aggressive haematological malignancies: interim results from a single-arm, open-label, pilot study. Lancet Haematol. 2017;4:e595–e606.

    Article  Google Scholar 

  5. 5.

    Malani D, Murumagi A, Yadav B, Kontro M, Eldfors S, Kumar A, et al. Enhanced sensitivity to glucocorticoids in cytarabine-resistant AML. Leukemia. 2017;31:1187–95.

    CAS  Article  Google Scholar 

  6. 6.

    Wilding JL, Bodmer WF. Cancer cell lines for drug discovery and development. Cancer Res. 2014;74:2377–84.

    CAS  Article  Google Scholar 

  7. 7.

    Garnett MJ, Edelman EJ, Heidorn SJ, Greenman CD, Dastur A, Lau KW, et al. Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature. 2012;483:570–5.

    CAS  Article  Google Scholar 

  8. 8.

    Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 2012;483:603–7.

    CAS  Article  Google Scholar 

  9. 9.

    Ghandi M, Huang FW, Jané-Valbuena J, Kryukov GV, Lo CC, McDonald ER, et al. Next-generation characterization of the Cancer Cell Line Encyclopedia. Nature. 2019;569:503–8.

    CAS  Article  Google Scholar 

  10. 10.

    Lee S-I, Celik S, Logsdon BA, Lundberg SM, Martins TJ, Oehler VG, et al. A machine learning approach to integrate big data for precision medicine in acute myeloid leukemia. Nat Commun. 2018;9:42.

    Article  Google Scholar 

  11. 11.

    Iorio F, Knijnenburg TA, Vis DJ, Bignell GR, Menden MP, Schubert M, et al. A landscape of pharmacogenomic interactions in cancer. Cell. 2016;166:740–54.

    CAS  Article  Google Scholar 

  12. 12.

    Yadav B, Pemovska T, Szwajda A, Kulesskiy E, Kontro M, Karjalainen R, et al. Quantitative scoring of differential drug sensitivity for individually optimized anticancer therapies. Sci Rep. 2014;4:5193.

    CAS  Article  Google Scholar 

  13. 13.

    Kumar A, Kankainen M, Parsons A, Kallioniemi O, Mattila P, Heckman CA. The impact of RNA sequence library construction protocols on transcriptomic profiling of leukemia. BMC Genomics. 2017;18:629.

    Article  Google Scholar 

  14. 14.

    Hänzelmann S, Castelo R, Guinney J. GSVA: gene set variation analysis for microarray and RNA-Seq data. BMC Bioinformatics. 2013;14:7.

    Article  Google Scholar 

  15. 15.

    Heo S-K, Noh E-K, Kim JY, Jeong YK, Jo J-C, Choi Y, et al. Targeting c-KIT (CD117) by dasatinib and radotinib promotes acute myeloid leukemia cell death. Sci Rep. 2017;7:15278.

    Article  Google Scholar 

Download references


We are grateful to the patients who donated samples to the study and thank the FIMM High Throughput Biomedicine Unit and Breeze DSRT data analysis pipeline teams for their support. The research was funded by the Finnish Cultural Foundation (DM), the Blood Disease Foundation Finland (DM), Finnish Hematology Association SHY (DM and AK), Ida Montinin Foundation (DM), EMBO short-term fellowship (AK), the Academy of Finland (Center of Excellence for Translational Cancer Biology; Grants 310507, 313267, 326238 to TA; 277293 to KW; iCAN Digital Precision Cancer Medicine Flagship Grant 1320185 to TA and CAH), Cancer Society of Finland (DM, AK, OK, TA, KW, and CAH), Sigrid Jusélius Foundation (to OK, KP, TA, and KW), EU Systems Microscopy (FP7), TEKES/Business Finland (to OK and KP), and Novo Nordisk Foundation (to KW; NNF17CC0027852). OK supported by the Knut and Alice Wallenberg Foundation, Swedish Foundation for Strategic Research, VR environment grant. MK supported by the University of Helsinki and Finnish Medical Foundation.

Author information




DM, AM, and OK designed the study. DM and AM performed drug testing experiments. DM, BY, and AK analyzed and visualized the data. DM generated hypotheses and interpreted results. DM and KKJ designed and performed flow cytometry experiments. MK performed cell line variant calling, and SP performed drug response data quality analysis. DM wrote the manuscript. MKo and KP obtained ethical permits, collected clinical samples and administered therapies. KP, MKo, TA, MW, KW, CAH, AM, and OK provided critical review. All authors contributed to and approved the final version of the manuscript.

Corresponding author

Correspondence to Disha Malani.

Ethics declarations

Conflict of interest

The senior authors have received collaborative research grants for other projects as listed: OK received research funding from Vinnova for collaboration between Astra-Zeneca, Takeda, Pelago, and Labcyte. OK is also a board member and a co-founder of Medisapiens and Sartar Therapeutics, and has received a royalty on patents licensed by Vysis-Abbot. KP received honoraria and research funding from Bristol-Myers Squibb, Celgene, Novartis, and Pfizer. CH received honoraria from Celgene, Novartis, and Roche, and research funding from Celgene, Novartis, Oncopeptides, Pfizer, and the IMI2 project HARMONY. KW received research funding from Novartis and Pfizer. MKo: research funding from AbbVie. The remaining authors declare that they have no conflict of interest.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Malani, D., Yadav, B., Kumar, A. et al. KIT pathway upregulation predicts dasatinib efficacy in acute myeloid leukemia. Leukemia (2020).

Download citation